Carlos R. Bachier, MD

Biography

Carlos R Bachier, MD is a board certified Hematologist / Oncologist with the Sarah Cannon Transplant & Cellular Therapy Program at Methodist Hospital in San Antonio, Texas. He is also the Medical Director of Research and Cellular Therapy.

While growing up, Dr. Bachier spent summers working at the clinic of his uncle, a pediatric endocrinologist. It was there he became interested in the field of medicine, as it combined his love of science with the "detective work," or finding out what is wrong with someone.

After completing a Bachelor of Science in Chemistry from Tulane University in New Orleans, LA, Dr. Bachier received his medical degree at University of Puerto Rico School of Medicine in San Juan, Puerto Rico. While in Puerto Rico, one of his mentors showed him how fascinating oncology treatment was. Dr. Bachier found oncology interesting because of the science of it, and it was the beginning of DNA abnormalities being discovered that would help determine future therapies.

After completing both his Residency in Internal Medicine and Fellowship in Hematology in San Juan, he came to University of Texas Health Science Center in San Antonio for a Fellowship in Hematology, Medical Oncology. He worked at the MD Anderson Cancer Center after completing his fellowship. In the late 1990's he returned to San Antonio and worked the Texas Transplant Institute where he eventually became program director. Dr. Bachier was then recruited to the Sarah Cannon Center for Blood Cancer as program director and as Director of Cellular Therapy Research at Sarah Cannon Research Institute. After six years as the Program Director at the Sarah Cannon Center for Blood Cancer in Nashville, Tennessee, he returned to Methodist Hospital in San Antonio.

He is a member of numerous professional associations, including American Society of Hematology, American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation. He is also a member of the Sarah Cannon Blood Cancer Network leading its Cellular Therapy Working Group.